Enzomed-D Tablet is a combination pharmaceutical formulation containing Trypsin 48 mg, Bromelain 90 mg, Rutoside 100 mg, and Diclofenac 50 mg, designed to provide effective anti-inflammatory, analgesic, and fibrinolytic actions. Trypsin and Bromelain are proteolytic enzymes that facilitate the breakdown of proteins, aiding in the reduction of edema and promoting the resolution of inflammation by enhancing fibrinolysis and improving microcirculation. Rutoside, a bioflavonoid, exhibits potent antioxidant and capillary-strengthening properties, which help reduce capillary permeability and fragility, thereby supporting vascular health and mitigating inflammatory responses. Diclofenac, a non-steroidal anti-inflammatory drug (NSAID), provides analgesic and anti-inflammatory effects by inhibiting cyclooxygenase enzymes, leading to decreased synthesis of prostaglandins involved in pain and inflammation. The synergistic action of these components makes Enzomed-D Tablet suitable for the management of acute and chronic inflammatory conditions such as musculoskeletal injuries, postoperative inflammation, and soft tissue trauma. It is recommended to be used under medical supervision, considering contraindications and potential drug interactions. Patients should adhere to prescribed dosages to minimize adverse effects and optimize therapeutic outcomes.